Delivery Order SPE2DB25D3202-SPE2DB25FTBDX
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a $69,305.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on May 27, 2025, with completion scheduled for May 28, 2025. This firm fixed price contract represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for severe asthma, eczema, and other inflammatory conditions, making this delivery order...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml syringes on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions,...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $13,593.94 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe...
- The Defense Logistics Agency awarded a $79,236.52 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL syringes on September 4, 2025, with completion targeted for September 5, 2025. This competitive, firm fixed-price award carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions, including asthma, atopic...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for Dupixent 200mg/1.14ml syringes totaling $11,966.22 under a firm fixed price contract. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a $18,016.58 delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Dupixent 300 mg/2 ml syringes with an ultimate completion date of May 5, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $6,146.28 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBDXDelivery Order
The Defense Logistics Agency awarded a $12,522.66 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL syringes on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed price contract for pharmaceutical supply delivery to be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, making this contract part of the Defense Health Agency's pharmaceutical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a leading pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen leverages this comprehensive contract vehicle to supply an extensive range of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare systems and other government agencies globally. The company's consistent track record of competitively awarded federal contracts demonstrates its capability to fulfill diverse pharmaceutical procurement requirements for the Defense Department and affiliated healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 8/19/25 |